ZURICH (Reuters) - Roche Holding AG said it will pay $725 million in cash to buy Seragon Pharmaceuticals, a privately-held biotech company that researches breast cancer treatments, and may pay up to another $1 billion based on certain milestones. The Basel-based…
Source: Roche to buy U.S. biotech firm Seragon for $725 million
Tuesday, July 1, 2014
Roche to buy U.S. biotech firm Seragon for $725 million
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment